Assertion: polypeptide's acid sequence | /r/AtLocation | seq id nos:2-16
Facets:
Source sentences:
text: Thus, when the variant is a variant of any of the sequences disclosed in SEQ ID NOS:2-16, such a variant usually comprises less than 15 modifications, typically 1-10 modifications, relative to the relevant amino acid sequence shown in SEQ ID NOS:2-16, such as 1-8, 2-8, 1-5, 1-3 or 2-5 modifications relative to the relevant the amino acid sequence shown in SEQ ID NOS:2-16.
text: Thus, when the variant is a variant of any of the sequences disclosed in SEQ ID NOS:2-16, such a variant usually comprises less than 15 modifications, typically 1-10 modifications, relative to the relevant amino acid sequence shown in SEQ ID NOS:2-16, such as 1-8, 2-8, 1-5, 1-3 or 2-5 modifications relative to the relevant the amino acid sequence shown in SEQ ID NOS:2-16.
text: NO 1 (or relative to the relevant fragment thereof having the amino acid sequence shown in SEQ ID NOS:2-16, e.g. SEQ ID NO:12).
text: NO 1 (or relative to the relevant fragment thereof having the amino acid sequence shown in SEQ ID NOS:2-16, e.g. SEQ ID NO:12).
text: Particular preferred variants of the present invention include a variant of SEQ ID NO:1 (or fragments thereof having the amino acid sequence shown in SEQ ID NOS:2-16, in particular SEQ ID NO:12), wherein said variant exhibits IFNG activity and which comprises at least one substitution selected from the group consisting of K12S, K12T, G18S, G18T, E38N, E38N+S40T, K61S, K61T, S65N+Q67S,
text: In another interesting embodiment of the invention, the variant of SEQ ID NO:1 (or fragments thereof having the amino acid sequence shown in SEQ ID NOS:2-16, in particular SEQ ID NO:12) comprises at least two introduced glycosylation sites, in particular at least two introduced N-glycosylation sites.
text: NO 1 (or relative to the relevant fragment thereof having the amino acid sequence shown in SEQ ID NOS:2-16, in particular SEQ ID
text: NO 1 (or relative to the relevant fragment thereof having the amino acid sequence shown in SEQ ID NOS:2-16, in particular SEQ ID
text: In another interesting embodiment of the invention, the variant of SEQ ID NO:1 (or fragments thereof having the amino acid sequence shown in SEQ ID NOS:2-16, in particular SEQ ID NO:12) comprises at least two introduced cysteine residues.